Circular 59/2023/TT-BTC introduces regulations on fees in medical sector, and the collection, transfer, management and use thereof. Such fees in the medical sector include:
a) Fees for processing of applications for
read more...Circular 59/2023/TT-BTC introduces regulations on fees in medical sector, and the collection, transfer, management and use thereof. Such fees in the medical sector include:
a) Fees for processing of applications for
read more...Guidelines:
A. Approved PI and PIL of all registered drug products shall be published by the FDA in the Verification Portal System at https://verification.fda.gov.ph and shall be updated monthly.
B. All MAHs
As part of a continual regulatory enhancement to ensure the quality standard of therapeutic products supplied in Singapore, Singapore’s Health Sciences Authority (HSA) will roll out a transition plan for
read more...Singapore HSA revised GN-05: Guidance on the Reporting of Adverse Events for Medical Devices with the following update:
– Included new section regarding Adverse Event Investigation
– Listed regulatory actions that HSA
Singapore’s Health Sciences Authority (HSA) updated the Medical Device Adverse Event Reporting Form for Medical Device Dealers (MDAR1 Form). As a management committee member of the International Medical Device Regulators
read more...HSA updates GUIDELINES FOR LABELLING STANDARDS OF HEALTH SUPPLEMENTS AND TRADITIONAL MEDICINES including clarification on labelling requirements on the name and address of local dealers for products manufactured in Singapore
read more...Singapore HSA included Medical Device Singapore Audit Program (MDSAP) certification as one of the acceptable lists of Medical Device’s QMS Certifications for medical device dealers (including manufacturer, importer and wholesaler).
Accordingly,
read more...Singapore’s Health Sciences Authority (HSA) updated EXPLANATORY GUIDANCE TO THE HEALTH PRODUCTS (ADVERTISEMENT OF SPECIFIED HEALTH PRODUCTS) REGULATIONS for Therapeutic Products (TP) Advertisement.
Minor revisions include:
– Redefining the list and terms
Singapore’s Health Sciences Authority (HSA) has finalised the updated GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices, based on the various feedback and comments received from
read more...